High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow

Blood

Volumn 113, Issue 10, 2009, Pages 2238-2244

  Melenhorst, J Joseph ^a   Scheinberg, Phillip ^a,b   Chattopadhyay, Pratip K ^b   Gostick, Emma ^c   Ladell, Kristin ^c   Roederer, Mario ^b   Hensel, Nancy F ^a   Douek, Daniel C ^b   Barrett, A John ^a   Price, David A ^b,c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; HLA A ANTIGEN; LEUKEMIA ANTIGEN; TETRAMER;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MYELOID LEUKEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC VARIATION; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 63849289233     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-151969     Document Type: Article

References (43)

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385-389.
2. Greiner J, Schmitt M. Leukemia-associated antigens as target structures for a specific immuno-therapy in chronic myeloid leukemia. Eur J Haematol. 2008;80:461-468.
3. Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88:2450-2457.
4. Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic pro-teinase 3 peptide preferentially inhibit chronic my-eloid leukemia colony-forming units. Blood. 1997; 90:2529-2534.
5. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
6. +T cells specific for human neutrophil elas-tase. Blood. 2004;103:3076-3083.
7. Oka Y, Tsuboi A, Taguchi T, et al. Induction of T1 (Wilms' tumor gene)-specific cytotoxic T ymphocytes by WT1 peptide vaccine and the esultant cancer regression. Proc Natl Acad Sci U.S.A.4;101:13885-13890.
8. Fujiwara H, Melenhorst JJ, El Ouriaghli F, et al. In vitro induction of myeloid leukemia-specific CD4 and CD8T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res. 2005;11:4495-4503.
9. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-1023.
10. Purbhoo MA, Boulter JM, Price DA, et al. The human CD8 coreceptor effects cytotoxic T-cell ctivation and antigen sensitivity primarily by mediating complete phosphorylation of the T-cell receptor zeta chain. J Biol Chem. 2001;276:32786-32792.
11. Wooldridge L, van den Berg HA, Glick M, et al. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T-cell receptor-antigen complexes at the cell surface. J Biol Chem. 2005;280:27491-27501.
12. Wooldridge L, Lissina A, Vernazza J, et al. Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol. 2007;37:1323-1333.
13. Choi EM, Chen JL, Wooldridge L, et al. High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J Immunol. 2003; 171:5116-5123.
14. Pittet MJ, Rubio-Godoy V, Bioley G, et al. alpha3 domain mutants of peptide/MHC class I multim-ers allow the selective isolation of high avidity tumor-reactive CD8T cells. J Immunol. 2003;171: 1844-1849.
15. + T-cell populations specific for persistent DNAviruses. J Exp Med. 2005;202:1349-1361.
16. + T-cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J Immunol Methods. 2008;338:31-39.
17. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLAA*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 1997;90:1751-1767.
18. Hutchinson SL, WooldridgeL,Tafuro S, et al.The CD8 T-cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem. 2003;278:24285-24293.
19. Perfetto SP, Chattopadhyay PK, Lamoreaux L, et al. Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry. J Immunol Methods. 2006;313: 199-208.
20. Whelan JA, Dunbar PR, Price DA, et al. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol. 1999;163:4342-4348.
21. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003;111:639-647.
22. Slifka MK, Whitmire JK, Ahmed R. Bone marrow contains virus-specific cytotoxic T lymphocytes. Blood. 1997;90:2103-2108.
23. Marshall DR, Turner SJ, Belz GT, et al. Measuring the diaspora for virus-specific CD8+ T cells. Proc Natl Acad Sci USA. 2001;98:6313-6318.
24. Klonowski KD, Marzo AL, Williams KJ, Lee SJ, Pham QM, Lefrancois L. CD8T-cell recall responses are regulated by the tissue tropism of the memory cell and pathogen. J Immunol. 2006; 177:6738-6746.
25. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001;291:2413-2417.
26. + T cells specific for respiratory viruses in the human lung. J Exp Med. 2005;202:1433-1442.
27. + T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007;204:595-603.
28. Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, et al. Persistence and responsiveness of immu-nologic memory in the absence of secondary lymphoid organs. Immunity. 2006;25:643-654.
29. + T cells with unique homing phenotype within the human bone marrow. Blood. 2008;112:3293-3302.
30. HayamaM, ShinoharaN, HigashiharaM, Eshima K. Accumulation of allo-MHC cross-reactive memory T cells in bone marrow. Immunol Lett.2008;117:154-160.
31. Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol. 2005;174:7654-7664.
32. Feuerer M, Rocha M, Bai L, et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer. 2001;92:96-105.
33. Bai L, Beckhove P, Feuerer M, et al. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer. 2003;103:73-83.
34. + memory T cells. Cancer Res. 2003;63:5582-5586.
35. Beckhove P, Feuerer M, Dolenc M, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotrans-planted autologous tumors. J Clin Invest. 2004; 114:67-76.
36. Choi C, Witzens M, Bucur M, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood. 2005;105:2132-2134.
37. Schmitz-Winnenthal FH, Volk C, Z'Graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 2005;65:10079-10087.
38. Muller-Berghaus J, Ehlert K, Ugurel S, et al. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease tage and disease duration. Cancer Res. 2006; 66:5997-6001.
39. Sommerfeldt N, Schutz F, Sohn C, Forster J, Schirrmacher V, Beckhove P. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res. 2006;66:8258-8265.
40. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol. 2005;174:1269-1273.
41. + T cell efficacy in vaccination and disease. Nat Med. 2008; 14:623-628.
42. Cole DK, Pumphrey NJ, Boulter JM, et al. Human TCR-binding affinity is governed by MHC class restriction. J Immunol. 2007;178:5727-5734.
43. + T cells with peptide-major histocompatibility complex class I tetramers. Cytometry A. 2008;73: 1001-1009.